Literature DB >> 8465203

Altered growth of human colon cancer cell lines disrupted at activated Ki-ras.

S Shirasawa1, M Furuse, N Yokoyama, T Sasazuki.   

Abstract

Point mutations that activate the Ki-ras proto-oncogene are presented in about 50 percent of human colorectal tumors. To study the functional significance of these mutations, the activated Ki-ras genes in two human colon carcinoma cell lines, DLD-1 and HCT 116, were disrupted by homologous recombination. Compared with parental cells, cells disrupted at the activated Ki-ras gene were morphologically altered, lost the capacity for anchorage-independent growth, grew more slowly both in vitro and in nude mice, and showed reduced expression of c-myc. Thus, the activated Ki-ras gene plays a key role in colorectal tumorigenesis through altered cell differentiation and cell growth.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8465203     DOI: 10.1126/science.8465203

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  239 in total

Review 1.  Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway.

Authors:  D W End
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

2.  Opposing roles of the extracellular signal-regulated kinase and p38 mitogen-activated protein kinase cascades in Ras-mediated downregulation of tropomyosin.

Authors:  Janiel M Shields; Heena Mehta; Kevin Pruitt; Channing J Der
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

3.  In vitro and in vivo growth inhibition of human malignant astrocytoma cells by the farnesyltransferase inhibitor B1620.

Authors:  Masanori Kurimoto; Yutaka Hirashima; Hideo Hamada; Hironaga Kamiyama; Shoichi Nagai; Nakamasa Hayashi; Shunro Endo
Journal:  J Neurooncol       Date:  2003-01       Impact factor: 4.130

4.  Three-dimensionally specific inhibition of DNA repair-related genes by activated KRAS in colon crypt model.

Authors:  Toshiyuki Tsunoda; Yasuo Takashima; Takahiro Fujimoto; Midori Koyanagi; Yasuhiro Yoshida; Keiko Doi; Yoko Tanaka; Masahide Kuroki; Takehiko Sasazuki; Senji Shirasawa
Journal:  Neoplasia       Date:  2010-05       Impact factor: 5.715

5.  T cell factor-activated transcription is not sufficient to induce anchorage-independent growth of epithelial cells expressing mutant beta-catenin.

Authors:  A I Barth; D B Stewart; W J Nelson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

6.  Collateral expression of proangiogenic and tumorigenic properties in intestinal epithelial cell variants selected for resistance to anoikis.

Authors:  J Rak; Y Mitsuhashi; C Sheehan; J K Krestow; V A Florenes; J Filmus; R S Kerbel
Journal:  Neoplasia       Date:  1999-04       Impact factor: 5.715

7.  Amphiregulin exosomes increase cancer cell invasion.

Authors:  James N Higginbotham; Michelle Demory Beckler; Jonathan D Gephart; Jeffrey L Franklin; Galina Bogatcheva; Gert-Jan Kremers; David W Piston; Gregory D Ayers; Russell E McConnell; Matthew J Tyska; Robert J Coffey
Journal:  Curr Biol       Date:  2011-04-21       Impact factor: 10.834

8.  Acquisition of anoikis resistance promotes the emergence of oncogenic K-ras mutations in colorectal cancer cells and stimulates their tumorigenicity in vivo.

Authors:  Mathieu Derouet; Xue Wu; Linda May; Byong Hoon Yoo; Takehiko Sasazuki; Senji Shirasawa; Janusz Rak; Kirill V Rosen
Journal:  Neoplasia       Date:  2007-07       Impact factor: 5.715

9.  Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response.

Authors:  Elda Grabocka; Yuliya Pylayeva-Gupta; Mathew J K Jones; Veronica Lubkov; Eyoel Yemanaberhan; Laura Taylor; Hao Hsuan Jeng; Dafna Bar-Sagi
Journal:  Cancer Cell       Date:  2014-02-10       Impact factor: 31.743

Review 10.  Trafficking of epidermal growth factor receptor ligands in polarized epithelial cells.

Authors:  Bhuminder Singh; Robert J Coffey
Journal:  Annu Rev Physiol       Date:  2013-11-08       Impact factor: 19.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.